...
首页> 外文期刊>Breathe >The Tuberculosis Network European Trials Group (TBNET): new directions in the management of tuberculosis
【24h】

The Tuberculosis Network European Trials Group (TBNET): new directions in the management of tuberculosis

机译:欧洲结核病网络欧洲试验小组(TBNET):结核病管理的新方向

获取原文
           

摘要

pThe Tuberculosis Network European Trials Group (TBNET) is the largest clinical research organisation in Europe. Educational activities include the TBNET Academy and the European Advanced Course in Clinical Tuberculosis. Four of their publications are reviewed to show how the clinical management of tuberculosis is changing./ph3Key points/h3pMost tuberculosis (TB) in contacts is found at their first visit./ppIn contacts of pulmonary TB patients, the likelihood of later TB is ≤3%./ppGenetic tests can indicate when another antimycobacterial drug in the same class might be effective (ie.g./i rifabutin when there is rifampicin resistance or which injectable to choose)./ppThe short-course “Bangladesh” regimen can only be rarely used in Europe./ppTreatment completion in multidrug-resistant TB should not be included as a successful outcome./p
机译:>结核网络欧洲试验组织(TBNET)是欧洲最大的临床研究组织。教育活动包括TBNET学院和欧洲临床结核病高级课程。审查了他们的四篇出版物,以显示结核病的临床管理方式正在发生变化。 >要点 >接触者中首次接触的大多数结核病(TB)。 > >在肺结核患者的接触中,以后发生结核的可能性≤3%。 >基因检测可以表明何时使用同一类别的另一种抗分枝杆菌药物可能有效(例如, i>对利福平有抗药性或可以选择注射的利福布汀。 >短程“孟加拉国”疗法仅在欧洲很少使用。 >在多药治疗中完成治疗耐药结核病不应被视为成功的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号